GlassScriptPhysician profile
Edward J Gindi
NPI 1013012772
$5,010.20
in general payments reported to CMS, 2019-2025
25 companies · $922 in 2025
The $922 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $414 · 2021: $452 · 2022: $1,213 · 2023: $664 · 2024: $652 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,483.10 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,016.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $634.93 | 2019-2025 | Nucala, Bexsero |
| Genentech USA, INC. | $312.25 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $238.03 | 2020-2024 | Dupixent |
| Kaleo, INC. | $172.33 | 2020-2024 | Auvi-Q |
| Pfizer INC. | $139.80 | 2019-2023 | |
| Optinose US, INC. | $131.89 | 2019-2022 | |
| Sanofi Pasteur INC. | $125.78 | 2020-2024 | |
| Amgen INC. | $115.52 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $109.06 | 2020-2025 | |
| Csl Behring | $104.85 | 2023-2025 | Haegarda, Andembry |
| Ars Pharmaceuticals Operations, INC. | $82.41 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $59.17 | 2022-2023 | |
| Cumberland Pharmaceuticals, INC. | $47.21 | 2022-2023 | Kristalose |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $44.10 | 2025 | Opzelura |
| Organon LLC | $38.64 | 2025 | Vtama |
| Nestle Healthcare Nutrition INC. | $25.00 | 2022 | |
| Shire North American Group INC | $22.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.83 | 2020 | |
| Sobi, INC | $18.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2019 | |
| Alk-Abello, INC | $17.81 | 2019 | |
| Seqirus USA INC | $17.29 | 2022 | |
| Merck Sharp & Dohme LLC | $14.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Gindi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.